Nanomedicine - Science topic
The branch of medicine concerned with the application of NANOTECHNOLOGY to the prevention and treatment of disease. It involves the monitoring, repair, construction, and control of human biological systems at the molecular level, using engineered nanodevices and NANOSTRUCTURES. (From Freitas Jr., Nanomedicine, vol 1, 1999).
Questions related to Nanomedicine
Nano-medicines are widely used in Oncology but are their actions on specific target cancer cells or they act on nirman cells also?
I am curious to know whether it is possible to explain and analyze targeted drug delivery methods with the mathematical and physical relationships that govern them, such as the Peppas Higuchi model?
What other models are available in this field?
For example, DNA has functional groups such as methyl groups and nanoparticles can interact with them and alter them. I was wondering if we have any technique by which we can quantify them or maybe do a qualitative analysis. Any leads would be great, Thank :)
Nanoparticle are used in Nanomedicine. Doctors have made it clear that these nps are not biodegradable; therefore, may cause damage to cells of tissues of organs they were used to treat. Is it safer to use Femto-particles which are products of Quantum Entanglement? Fps are proton - antiproton pairs.
I have biofunctionalized o-MWCNT with 2 recombinant proteins; the proteins had 10 histidine tags to attach to the o-MWCNT. After dispersing in media (without serum) to incubate with cells less than 24h o-MWCNT intensively aggregate (37C incubator). I have changed the media (less glucose and salt) and tried to improve biofunctionalization (for better coating), although the measures were inefficient.
In targeted drug delivery, when nanoparticles release their drugs, how can we estimate the concentration of the drugs at the tumor?
Is there any practical example where multiple nanoparticles release a single drug?
Nanomedicine - Future Medicine;
International Journal of Nanomedicine - Dove Press;
Nanomedicine: Nanotechnology, Biology and Medicine
Targeted drug delivery through nanoparticle, the success rate of drug delivery at the tumor is 5%.
Is there any other success rate reference?
In drug delivery, for efficacy, the drug concentration needs to be within LEC and MSC. How can we define that concentration?
I have been trying to find any method for co-culture. My aim is to introduce a ScFv construct into the nanocarrier. I researched but I could not find an exact method. May you help me ? Also, can I design a nanocarrier with receptors? Is it possible? :)
Thanks and have a nice day.
I cannot find the IC50 value of 5-FU against HT-144 cancer cells, as determined via cytotoxicity analysis. I shall be thankful if someone help me with relevant literature.
Does anyone know what the preferred concentration of chitosan coated PLGA nanoparticles for MTT assay? I am starting with a 10mg/ml concentration and have not gotten good results with a 1:2 serial dilution - any suggestions?
The main (and generalistic) advantages and disadvantages of each type of nanosystem have been widely pointed out in literature. However, the advantages and disadvantages stated are too broad and sometimes overlap. Of course, it can depend on several factors: the targeted tissues; the loaded compounds; the type of administration; the final formulation; industrial scalability; among others. This way, this question aims at opening a debate to untangle and explore further the potentialities of each nanosystem and, more specifically, the (1) differential and (2) more specific applicabilities of each one towards the right final choice for the preconized biomedical application. Personal experiences and opinions are deeply welcomed!
Nano-based approaches for cancer therapeutics are undoubtedly important to tackle cancer. However, it is widely known that each cancer type has its own peculiarities and heterogeneity. This way, which are the main aspects / considerations you consider a "signature" and unique for each cancer type in what concerns nanomedicine-based therapies?
#cancer #nano #nanomedicine
More then 30 nanomedicine has been approve by FDA and in clinical practice. How they overcome the challenges such as large scale production, toxicity issues, instability in body or storage conditions etc which are the hurdles for commercialization of new experimental nanomedicine. My question is then how the approved nanomedicine overcome the mentioned challenges?
I'm interested in the required knowledge,skills and branches of science that I may need to study in order to make a research in nano-medicine for cancer therapy. A list of references or something similar would be of great help to me. Thanks for all your kind responses.
Dear Sir/Madam, I invited as a guest editor from high quality journals to handle special issues. If anyone can prepare a review similar to my review papers, particularly about a natural product in cancer prevention with focus on the structure activity relationship and mechanism of action, please kindly let me know to send an official letter. At this stage you should just send the title, authors and affiliation and abstract. Please kindly let me know as soon as you can. The suggested deadline for sending review is about 3 month. Best wishes, Suggeted topic: Genotoxicity of different agents and possble protection. Reducing side effects of radiotherapy and chomotherapy. Next generation of cancer therapy; Natural products. Natural products as novel therapeutic compounds. Radiation protection.
Which areas will develop further and gain momentum?
Which ones will be showing less interest?
Major targets? Major hopes? Which bounderies need to be overtaken? Which ones will remain unmatched?
Which is / will be The greatest challenge?
I am planning to do a phototoxicity experiment in which I need to apply an UV Energy lower than the highest non citotoxic energy. Based on literature it should be around 5J/cm^2 for my cell line so I dont know if I can use my UV lamp and at which distance (5 cm or more) in order not to kill the cells with the irradiance. Could someone help me with the calculations?
I am trying to determine the best possible method to measure the impedance on my monolayer of MDCK (Madin Darby Canine Kidney) epithelial cells.
Does this require a specific metallic coating (via sputter coater or another method) on/ under (as a membrane the cells would grow on) my monolayer or would the liquid media itself simple provide the conductive element required?
Bhasma is classical calcinated nano medicine. Mandoor is mentioned as one the main ingredient of Bhringraj Tailam. Many or practicinor use kashisha bhasma also in hair oil. How can we justify the effect of these bhasma on hair treatment. Bhasma has poor absorption through skin. Why classical texts mention mandoor like mineral in hair oil?
I've experimented sterilization with autoclave, but the melting point of used polymer polycaprolactone is 60 ° C and so it is not suitable for my formula...and so on sterilization with filtration because I have microparticles.
For a research i'm working on, I've been reading different articles and have seen different protocols for the preparation of liposomes.
The article that i have been reading and basing my research on, is using a 3:1 ratio of chloroform/methanol, while the SOP of my university is using a 1:1 ratio for the dissolution of the lipids. Both procedures allow the formation of 200 nm liposomes.
How much does this matter for the preparation of the liposomes and which ratio should I use?
The mentioned article is:
Corbo, C., Molinaro, R., Taraballi, F., Toledano Furman, N. E., Sherman, M. B., Parodi, A., … Tasciotti, E. (2016). Effects of the protein corona on liposome-liposome and liposome-cell interactions. International Journal of Nanomedicine, 11, 3049–3063. https://doi.org/10.2147/IJN.S109059
I'am a student in the final year of M.Sc.+ M.Tech in Nanotechnology, I would like to work on a project focused on the biological applications of Nanotechnology like drug delivery, anti-cancer, nanomedicine and bio-sensors. The project will be a part of my master degree final semester coursework and will commence from January 2018. I have attached my CV for any information regarding my qualifications and research experience.
Any prospective leads and suggestions would be highly appreciated.
I'm working on a project on drug delivery system. My team is researching on the conjugation of HPMC (a semi-synthesized polymer) and Zein (a protein extracted from corn). If anyone knows any information about how to conjugate those two (maybe make them become a micelle we suppose), please let me know. Thank you so much for your support. You are helping to create a new tool for advanced nanomedicine application in enhancing the dissolution rate of poorly water soluble drugs!
I need to know how to change pH during release from pH 1,2, 6,8 and 7.4. the amount of HCl, NaOH used full steps in details. and which method is preferred
I am trying to transform S.aureus/E.coli bacterial cells with naked Iron Oxide nanoparticles (200-250nm) with the aim of generating bacteria with magnetic properties. I am bombarding cells in 1ml suspension made of PBS and 0.75M Sorbitol. However, I am unable to confirm transformation after bombardment. There are a lot of particles in the suspension after the bombardment that respond to magnets but how can I confirm whether these particles are inside the cells, outside the cells or attached to the bacteria from outside? I am using 500ug of nanoparticles per bombardment and cells in PBS (not in media) because bombarding them in nutrient medium may cause them to grow and eventually lose the particles.
Hello, I am working on synthesis of nano medicine in conjugation.For that I have to prepare silver nano particles through reduction method using NaOH as a reducing agent and silver salt as an oxidising agent while the flow of reaction pH of the solution mixture will be reached up to 8 which will mark the end of reaction. I am wondering for the reason why pH 8 why not less or more. What is the speciality of pH 8 which will mark end of reaction and synthesis of desire product??
Hi, I am working upon nano medicines. Drugs are made targeted to the site of action. So, I am wondering for how a drug can be made a targeted one. How does it reach to specific area without prior loss or being harmed?
actually particles less than 5 nm are rapidly cleared from the circulation through extravasation or renal clearance and when the size ranges increases to 15 micrometers accumulation of particles may occur, i wish to know is there any required particle size of nano formulation to target various cancer cells...
I am trying to make PLGA nanoparticles, I need it to be ~100nm.
I am using different methods, with the nanoprecipitation, this is the protocol:
76mg of PLGA (MW 12 kDa, 50:50 lactide/glycolide molar ratio). Prepared in 5mL of acetone. I heat with stirring for moments to dissolve the polymer. Then, I add 14mg of Pluronic1 F-108. Add them to aqueous (50 ml) solution under vigorous magnetic stirring and left to stir overnight (rate of addition of organic phase (1 mL/min) to aqueous phase).
The next day, I centrifuge at 10,000 rpm for 20 minutes (Not sure if I should convert that to xg or not), wash twice with diH2O (I get a problem in resuspend them, they adhere too much to the wall of the tube (50mL tube)). I found aggregations when I used higher speed and removed them by quick spin the sample and take the supernatant.
Then, I snap freeze them using liquid nitrogen, and finally lyophilized under vacuum for 48 hours.
For the characterization part: I am using Malvern Zetasizer ZS90. Reconstitute them after lyophilization in PBS "also tired diH2O". I add around 2-5mL. Then, serial dilution, 10uL of the sample into 990uL, the second is 20uL of the diluted into 980uL.
Every time I try different SOP, I got a very poor sample, either the Z-average (88-900) Or PDI which is always above 0.1 (0.3-0.8). And most of the time it stop and asks me to change the sample because it's poor.
I tried two samples and changed the following:
Speed of adding organic phase, it was drop-wise and 1mL/min
Speed of stirring during addition of organic phase, I used 360rpm
What should I change? The concentrations? The characterization part? Should I try different solvent or surfactant? The speed of centrifuge?
i am not an expert in membrane science,
but i was wondering if that possible to deplete/remove or deactivate all glycoprotein on cell membrane by adding some chemical agent in cell culture medium?
if yes, can you give me the related article ? and the name of the chemical agent
if not, maybe you can explain to me, and correct my misunderstanding
We are running this in-vivo experiment that involves coating of vicryl suture with a protein to assess its effect on wound healing. I would like to confirm that the coating was successful but to do this, I would need to chemically detach the protein from suture before ELISA.
I would appreciate suggestion from anyone with experience in this.
My question is caused by a dual voice of research papers I have read. On one hand graphene or it's derivatives is used in composites with potential medical applications (stents, implants). I've even encountered one where a nitiol implant was covered with graphene (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3622089/) without adverse effects to cells.
On the other hand graphene on it's own is not the friendliest material to handle. From rash in case of direct contact with the skin to news that with it's small size graphene particles can get inside cells and destroy them from within. A dental filling with graphen (to increase the durability) was deemed too toxic to use in patients.
I'm hoping for some personal opinions or other infromation on that matter
Hi, I am trying to administer orally MPs (approx 400 um in size, disperse in water) to ICR mice but facing difficulties like aggreagtion of MPs in gavage tip or in syringe. I tried different size gavage use for mice and rats. I will appreciate any suggestion to solve this problem.Thanks
I want to study aggregation of my particles in blood in vitro. I have found this paper http://www.sciencedirect.com/science/article/pii/S1549963407000056 but I have some questions about attenuation and refractive coefficient of the sample.
I am seeking potential collaborators for an NIH/NCCAM grant or private foundation grant to evaluate for low levels of plant, animal, and mineral/metal nanoparticles in a form of alternative medicine and/or to compare biological effects with modern nanoparticle forms of same source material. Please contact me if this interests you.
I need to detect intracellular ROS of HDFs after treatement with nanoparticles.
Could any one please tell me the maximum concentration of ZnO nanoparticles that can be considered as bio-compatible based on blood hemolysis studies. Does it depend on nature of the animal from which the blood is taken and studies are carried out?
zein nanoparticle tend to aggregate and coagglutinate when i added it to DMEM media to treat cells
I use tween80 as surfactant \ pluronicF86.
can I incubate the cells with nanoparticle dissolved in ddwater with no Media
Something that can be used in aqueous media to prevent microorganism growth, and that is does not show UV absorption between 200 - 300 nm?
We all know that Silver nanoparticles (AgNPs) has an antibacterial proprieties. When added to a polymer matrix (e.g PCL), what's is the maximum percentage of this antibacterial charge (AgNPs), to have a better antibacterial properties ?
A nanomotor is a molecular or nanoscale device capable of converting energy into movement. It can typically generate forces on the order of pico-Newtons. The applications consists of directed drug delivery and novel treatments in nano-onchology. For instance, those nanomotors are categorized as below:
1- Molecular motor proteins found in living cells.
2- DNA nanomachines.
3- Chemically powered or UV triggered artificial nanomotors.
4- Catalytic nanowire motors, such as Pd-CNT nano tube and fuel-driven catalytic nanomotors.
5- Bubble-powered catalytic microtube microengines.
Your comments are appreciated !?
I have to measure globule size of micro emulsion which was incorporated into Hydrogel ( Hydrogel was prepared by incorporating micro emulsion in the Hydro gel of carbopol 940).
There are many instrument available for measurement of globule size of microemulsion in liquid form, but i have not any idea about to measurement of globule size in gel form.
Would like know if there is any instrument other than ICP-MS (inductively coupled plasma mass spec) that I could use to determine the amount of AuNPs taken up by the liver and other organs during in vivo studies. Thanks
If respiratory infections are exacerbated by exposure to particles then another explanation is mechanical removal at an oxygen exchanging surface aside from biochemical interactions inside the cell. There might be no significant biochemical interaction between nanoparticles and the immune system. Reducing the availability of O2 to alveoli surfaces reducing normal cell function weakening them when infection occurs could explain survey data, no? Nanoparticles simply block O2 path?
I have prepared the CaP/Ag nanoparticles for the biomedical applications in drug delivery,give the suggestion for using surfactants.
I need to find a company/facility that is interested in loading a drug inhaler cartridge (something generally used for asthmatic people) with monodisperse microsize particles. These are solid spheres in the range of 1-10 um. I want a cheap and quick way to create an aerosol using this inhaler for the testing of samplers. Any suggestion and contacts are very welcome.
Will there be any difference if the material showing non stoichiometric crystal defect at nanoscale.
The nanoparticles I am working on aggregates in physiological media and conditions. In-vivo they seem to accumulate in the liver and spleen, and not in the target site (tumor). I want to compare the hemocompatibility of the unmodified nanoparticles and the PEGylated nanoparticles. I did a in-vitro hemolysis assay using mouse blood, and found unmodified version causes 25% hemolysis.
I would now like to do some more checks to compare the hemocompatibility of the nanoparticles in-vivo.
1.Will doing activated partial thromboplastin time (APTT) or prothrombin time (PT) make any sense to my data?
2.Does nanoparticles (no heparin) administered intravenously cause activation of clotting factors by any chance?
3.What other tests can be done to check hemocompatibility in-vivo?
- Please help me in calculating plasma drug concentration-time curve (AUC). I evaluated two different Nanoparticles formulation for their colon-specific drug delivery ability in Rats and compare bioavilability from 0-24hrs by taking blood samples from tail. i got conc-time curve from which i can calculate Tmax and Cmax. I need Help in calculating AUC.
I have bio-synthesized a bialloy metal manoparticle and now I want to cap this nanoparticle with a drug .
There are some method which I learnt but all were for the chemically synthesized nanoparticles.
Could anyone please tell me the preferred concentrations of ZnO nanoparticles for MTT assay against lung and breast cancer cell lines?
I am trying to conjugate a peptide molecule of size ranging from 10 -40 KDa to the silver nanoparticles size of 40-120 nm (from SEM analysis). For this I am using charge dependent binding of the protein (at pH 8.0) to the nanoparticles, still I am unable to get a prolonged stability of the conjugates (Silver Nanoparticle-peptide), to maintain stability would you please suggest any protocol for the nanoparticle protein conjugation.
The TUNEL labeling for apoptosis in the tumor tissues was visualized by BrdUTP incorporation, detected using red fluorescence labeled anti-BrdU monoclonal antibody. However, the overall red intensity is low. I'm wondering whether it's acceptable or not to adjust the overall brightness/contrast for all the groups.
Can a metal oxide nanoparticle having lower surface area exhibit better bactericidal property than a metal oxide (same material) nanoparticle having higher surface area? If so, then what could be the factors which are responsible for this behaviour?